Market Place
Sourcing Support
ARCA Biopharma Completes Merger with Oruka and Reverse Stock Split
29 Aug 2024 //
GLOBENEWSWIRE
ARCA Biopharma Updates Special Dividend Amount in Merger with Oruka Therapeutics
26 Aug 2024 //
GLOBENEWSWIRE
ARCA Biopharma Updates Special Dividend For Oruka Therapeutics Merger
26 Aug 2024 //
GLOBENEWSWIRE
ARCA Biopharma Announces 1-For-12 Reverse Stock Split For Oruka Merger
23 Aug 2024 //
GLOBENEWSWIRE
ARCA Biopharma Declares Special Dividend, Merger With Oruka Therapeutics
16 Aug 2024 //
GLOBENEWSWIRE
ARCA Biopharma Reports Q2 2024 Results And Corporate Update
01 Aug 2024 //
GLOBENEWSWIRE
ARCA biopharma Announces Q1 2024 Results, Update
25 Apr 2024 //
GLOBENEWSWIRE
Arca Biopharma Investor Alert by the Former Attorney General of Louisiana
05 Apr 2024 //
BUSINESSWIRE
ARCA biopharma and Oruka Therapeutics Announce Merger Agreement
03 Apr 2024 //
GLOBENEWSWIRE
Paragon’s hub-and-spoke biotech model yields another reverse merger
03 Apr 2024 //
BIOPHARMADIVE
ARCA biopharma Announces 2023 Financial Results
01 Feb 2024 //
GLOBENEWSWIRE
ARCA biopharma Announces Third Quarter 2023 Financial Results
18 Oct 2023 //
GLOBENEWSWIRE
ARCA biopharma Announces Second Quarter 2023 Financial Results
21 Jul 2023 //
GLOBENEWSWIRE
ARCA biopharma Announces First Quarter 2023 Financial Results
24 Apr 2023 //
GLOBENEWSWIRE
ARCA biopharma Announces 2022 Financial Results and Provides Corporate Update
24 Feb 2023 //
GLOBENEWSWIRE
James Flynn Joins ARCA biopharma Board of Directors
19 Dec 2022 //
GLOBENEWSWIRE
ARCA biopharma Announces Third Quarter 2022 Financial Results
28 Oct 2022 //
GLOBENEWSWIRE
As cash dips below $50M, Arca ups search for strategic options
03 Aug 2022 //
FIERCEBIOTECH
ARCA biopharma Announces Second Quarter 2022 Financial Results
02 Aug 2022 //
GLOBENEWSWIRE
Jacob Ma-Weaver Joins ARCA biopharma Board of Directors
21 Jun 2022 //
GLOBENEWSWIRE
ARCA biopharma Retains Ladenburg Thalmann to Support Strategic Options Review
05 May 2022 //
GLOBENEWSWIRE
ARCA biopharma Announces First Quarter 2022 Financial Results
02 May 2022 //
GLOBENEWSWIRE
ARCA biopharma Establishes Special Committee of the Board of Directors
18 Apr 2022 //
GLOBENEWSWIRE
ARCA biopharma announces Phase IIb Covid-19 therapy trial data
01 Apr 2022 //
CLINICALTRIALSARENA
ARCA bio Reports Topline Results for ASPEN-COVID-19 Phase 2b Clinical Trial
31 Mar 2022 //
GLOBENEWSWIRE
ARCA biopharma Announces 2021 Financial Results and Provides Corporate Update
14 Mar 2022 //
GLOBENEWSWIRE
ARCA biopharma completes enrolment in Phase IIb Covid-19 therapy trial
03 Dec 2021 //
CLINICALTRIALSARENA
ARCA biopharma Announces Third Quarter 2021 Financial Results
02 Nov 2021 //
GLOBENEWSWIRE
ASPEN-COVID-19 Data and Safety Monitoring Committee Recommends Continuing Ph 2b
30 Oct 2021 //
PRESS RELEASE
ARCA biopharma Enrolls First International Patient in Phase 2b Trial rNAPc2
16 Sep 2021 //
GLOBENEWSWIRE
ARCA biopharma to Present at the Q3 Virtual Investor Summit on August 18th
16 Aug 2021 //
GLOBENEWSWIRE
ARCA biopharma Announces Second Quarter 2021 Financial Results
04 Aug 2021 //
GLOBENEWSWIRE
ARCA biopharma Provides Update on ASPEN-COVID-19 Phase 2b Clinical Trial
13 Jul 2021 //
GLOBENEWSWIRE
Arca biopharma to Present at Access to Giving Virtual Investor Conference
09 Jul 2021 //
GLOBENEWSWIRE
ARCA biopharma Announces rNAPc2 COVID-19 Patent Assignment Agreement
07 Jul 2021 //
GLOBENEWSWIRE
ARCA biopharma Announces 2020 Financial Results and Provides Corporate Update
18 Mar 2021 //
GLOBENEWSWIRE
ARCA Announces First Patients Enrolled in ASPEN-COVID-19 Phase 2b Trial
15 Dec 2020 //
GLOBENEWSWIRE
ARCA Biopharma’s AB201 for COVID-19 Gets Fast Track
23 Nov 2020 //
CONTRACTPHARMA
AB201 DevP as a Potential for COVID-19 Receives U.S. FDA Fast Track Designation
23 Nov 2020 //
FIRSTWORLDPHARMA
ARCA biopharma’s AB201 secures IND approval for Covid-19 trial
08 Oct 2020 //
CLINICALTRIALSARENA
ARCA biopharma Announces FDA Approval of IND Application for AB201
07 Oct 2020 //
GLOBENEWSWIRE
ARCA biopharma Announces Submission of IND Application to U.S. FDA for AB201
21 Sep 2020 //
BIOSPACE
ARCA Announces Completion of FDA Pre-IND Consultation for AB20
12 Aug 2020 //
BIOSPACE
ARCA Biopharma Announces $9.4 Million Registered Direct Offering
01 Jun 2020 //
GLOBENEWSWIRE
ARCA biopharma Announces AB201 Development Program for Treatment of COVID-19
28 May 2020 //
GLOBENEWSWIRE
